Immunosuppressive Drugs Market

Immunosuppressive Drugs Market Overview

The immunosuppressive drugs market size is estimated to reach USD 9.98 billion by 2032 at 7.5% CAGR during the forecast period 2023-2032. The market of immunosuppressive drugs is a rapidly growing market. These drugs are used for treating autoimmune disorders and for preventing the rejection of transplanted organs. Any organ transplantation will not be successful without these drugs. Therefore, these drugs play a vital role in the medical world.

Immunosuppressive drugs are also used for the treatment of autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, psoriasis, etc. These drugs are also known as anti-rejection drugs as they prevent the rejection of transplanted organs by our body.  

The Lifestyle change and increasing obesity rate is making us prone to various disorders. The cases of organ failure are all increasing every day. Statistics reveal that only for kidneys a million transplantations are performed worldwide each year. The numbers will shoot up if all Transplantations are counted. Therefore, immunosuppressive drugs have a good market hold.

Memo Therapeutics, a biotech company based in Switzerland, has completed a Series C financing round valued at $27.67 million (SFr 25 million) in November 2023. The biotech company has announced that the proceeds will be used to finance a Phase II trial that will investigate its candidate, AntiBKV. Pureos Bioventures, a Swiss venture capital (VC) company, led the round, with existing investors such as Swisscanto, Vesalius Biocapital, and Adjuvant Capital also participating. Memo's Phase II trial, which is investigating a treatment for BK polyomavirus (BKV) infection in kidney transplant recipients, will be completed with the funds raised in the round, according to a press release issued on November 2. 2024 is the anticipated year for the trial's data. BKV is an opportunistic virus that can reactivate in patients post-transplant as a result of the immunosuppressive drug regimen. Memo reports that it is activated in 40% to 50% of kidney transplant recipients, with 10% of these cases resulting in BKV-associated nephropathy. Consequently, the virus has the potential to significantly reduce the survival rates of renal transplant grafts. At present, there are no FDA-approved treatments for BKV infection; therefore, the standard treatment is to decrease the dosage of immunosuppressive medications.

Arch 2024: TRACT Therapeutics and Taiwan Bio Therapeutics are delighted to announce a poster presentation at the 2024 annual meeting of the American Transplant Congress (ATC), which will be held in Philadelphia, PA from June 1-5, 2024. TRACT Therapeutics, a clinical-stage biotechnology company, and Taiwan Bio Therapeutics, a world-class expert in cell therapy manufacturing, established a strategic partnership in November 2023 to advance a novel regulatory T cell (Treg) therapy approach to preventing rejection in solid organ transplants. The companies will collaborate to initiate a Phase 2 clinical trial that will examine the potential of Treg therapy to decrease the necessity for immunosuppressant medications in living donor kidney transplant recipients. The research institutions will be situated in Taiwan and the United States. The ATC offers a dynamic platform for professionals to exchange insights on their work and experiences in the field of transplantation medicine, which is a pressing need. This platform is designed to develop more effective treatments for patients confronting an organ transplant. The regulatory T cell therapy developed by TRACT has the potential to significantly alter treatment paradigms, thereby enhancing the quality of life and patient outcomes.

Covid 19 Analysis of Immunosuppressive Drugs Market

The covid pandemic had a strong impact on the market of immunosuppressive drugs. Hospitals and diagnostic centers were overburdened with covid cases. So, the demand for immunosuppressive drugs fell with fewer patients reaching for treatment.

The restrictions imposed for curbing covid spread disrupted the supply chains. Moreover, urgent demand for antiviral drugs made pharmaceutical companies make changes in their production rate. Thereby, causing the growth rate to deviate from the previous rate. However, the market is quickly picking up its growth rate after the relaxation of restrictions in different regions. 

Immunosuppressive Drugs Market Dynamics

Drivers

The rising prevalence of autoimmune diseases is the major growth-promoting factor. According to a report of the National stem cell foundation, more than 4% of the global population suffers from autoimmune diseases.

Immunosuppressive drugs are a must for people who develop autoimmune diseases such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, psoriasis, etc.  These drugs have to be taken for a lifetime for such patients, so the market demand is never down. Moreover, these drugs are also necessary to make organ transplants successful. Hence with the increasing rate of transplantations, the valuation of the market is also increasing. 

Restraints

The collective effect of various factors is restricting the market growth of the immunosuppressive drugs. Among those factors, the side effects of these drugs are the major ones. Immunosuppressive drugs lower immunity, which may expose our bodies to other fatal diseases.

Moreover, these drugs have to pass through stringent rules and regulations in different countries to reach the customers. Hence, such rules are too hindering market growth. 

Technology Analysis

Immunosuppressive drugs are chemicals that prevent the rejection of transplants by our system by suppressing the immune response. These drugs are also a treatment for autoimmune disorders, where our immune system begins to attack our healthy cells.  For example diseases like Rheumatoid arthritis, Multiple sclerosis, Type 1 diabetes mellitus, Graves' disease, etc.

Immunosuppressive drugs are also important for the success of organ transplantations. These drugs are widely used by patients who undergo transplantation of kidney, liver, heart, tissues, etc. These drugs act by overcoming our immune response to protect the foreign grafts.

In the case of autoimmune disorders, our body assumes the cells in some regions to be foreign bodies and begins attacking them, to kill these cells. Therefore patients suffering from these diseases need to take immunosuppressants for a lifetime. In the case of organ transplantation too, our system tries to get rid of foreign cells by attacking them. The patients undergoing transplantation have to take these drugs till their body becomes normal with the new organs. 

Study Objectives

This report aims to provide a complete market overview of the Immunosuppressive drugs. The specific objectives of this market report are given below:

• To analyze and forecast the market of immunosuppressive drugs in terms of value and volume.
• To provide information about the impact of covid 19 on market growth.
• To identify the problems and market prospects of the Immunosuppressive drugs
• To give details about the technological viability of the product
• To provide an overview of the regional market and potentially growing segments.
• To identify the key players of the industry

Immunosuppressive Drugs Market Segment Overview

Segmentation of the Global immunosuppressive drugs Route of Administration Outlook 

• Oral Drugs
• Intravenous Drugs
• Others

Oral drugs are the most widely used type, hence hold the major market share. They are easy to use and have fewer side effects. However, intravenous injection is recommended for a more specific application. Although they have greater efficiency it will lead to more side effects.

 Segmentation of the Global immunosuppressive drugs Drug Class Outlook

• IMDH inhibitors
• mTOR inhibitors
• Antiproliferative agents
• Corticosteroids
• Calcineurin inhibitors
• Monoclonal antibodies
• Others

 The Calcineurin inhibitor class of drugs occupies the major market share. These drugs are highly effective to counteract autoimmune response, post organ transplantation. This drug segment is also showing a higher growth rate as they are the most widely used drugs for kidney transplants. They work by inhibiting calcineurin, a major rejector of Kidney transplants.

Segmentation of the Global immunosuppressive drugs application Outlook

• Organ transplants
  • Kidney Transplants
  • Liver Transplants
  • Heart Transplants
  • Others
• Autoimmune disease
  • Localized Autoimmune Disease
  • Systemic Autoimmune Disease

The autoimmune disease segment dominates the market over organ transplants. There has been a significant rise in cases of Autoimmune disorders globally which is contributing to the market growth. Thus, this segment shows a higher growth rate too. However, the organ transplantation market is a fast-growing segment. Organ transplantations are becoming common and simpler, which is indeed contributing to its growth.  

Segmentation of the Global immunosuppressive drugs end-user Outlook

• Organ transplant centers
• Hospitals and clinics
• Others

Hospitals and Clinics dominate the end-user market segment. Hospitals and clinics are the primary places of treatment for most problems. Therefore, they have higher market value and a higher growth rate. 

However, organ transplant centers are witnessing a higher growth rate. They have more technological facilities to serve the purpose. Moreover, these centers have links with organ donation camps so, can serve more patients. 

Regional Analysis

The different regional markets for the global immunosuppressive drugs market are:

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
• Rest of the World
• Middle East
• Africa
• Latin America

Americas hold the largest market of the global immunosuppressive drugs market. More prevalence of autoimmune disorders in this region is the major contributing factor. Moreover, advancements in medical technology and better health infrastructure act as boosters to the growth. According to a report of the National Institute of Health ( NIH, 2017 ), more than 7 % of Americans suffer from autoimmune disorders. The percentage is still rising, so is the market share for the drugs. 

Europe is also experiencing a rise in several cases of Autoimmune Diseases. This will drive the market growth there.  Moreover, better infrastructure facilities and R & D spending will support the growth.

The Asia Pacific is the fastest-growing segment. A higher population and increasing disposable income are driving the market growth. Moreover, government efforts towards the modernization of health infrastructure will increase the market value. 

The Middle East and Africa are showing feeble growth owing to less prevalence of autoimmune diseases.

Competitive Landscape

The major global companies playing a key role in the immunosuppressive drugs market are :

• Accord Healthcare (UK)
• Astella Pharma (Japan)
• Bristol-Myers Squibb Company (US)
• Genzyme Co. (Switzerland)
• Hoffmann-La Roche AG (US
• GlaxoSmithKline PLC (UK)
• Glenmark Pharmaceuticals, Inc. (India)
• Mylan Laboratories Inc. (US)
• Pfizer Inc. (US)
• Novartis AG (Switzerland)
• Actavis, Inc.
• Zydus Cadila (India)

Recent Developments

November 2023Novartis receives FDA approval for its new oral immunosuppressant, Kynviq® (ledipasvir/sofosbuvir), for the treatment of chronic hepatitis C virus (HCV) infection in adults with compensated liver disease who have not received prior antiviral treatment. Kynviq® is a combination of ledipasvir, an NS5A inhibitor, and sofosbuvir, an NS5B inhibitor.GlaxoSmithKline (GSK) announces that it has submitted a New Drug Application (NDA) to the FDA for its investigational drug, Benlysta® (belimumab), for the treatment of systemic lupus erythematosus (SLE). Benlysta® is a monoclonal antibody that targets B-lymphocytes, a type of white blood cell that plays a role in the development of SLE.Bristol Myers Squibb (BMS) announces that it has received FDA approval for its new drug, Opdivo® (nivolumab), for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). Opdivo® is a checkpoint inhibitor that targets PD-1, a protein that helps cancer cells evade the immune system. October 2023Sanofi announces that it has received FDA approval for its new drug, Dupixent® (dupilumab), for the treatment of moderate-to-severe atopic dermatitis in adolescents and adults who are candidates for systemic therapy. Dupixent® is a biologic drug that targets the IL-4 and IL-13 signaling pathways, which play a role in the inflammation associated with atopic dermatitis.Pfizer announces that it has submitted a New Drug Application (NDA) to the FDA for its investigational drug, Xeljanz® (tofacitinib), for the treatment of ulcerative colitis (UC). Xeljanz® is a small molecule that inhibits Janus kinase (JAK), a protein that plays a role in inflammation.AbbVie announces that it has received FDA approval for its new drug, Rinvoq® (upadacitinib), for the treatment of rheumatoid arthritis (RA) in adults who have not responded adequately to or are intolerant of methotrexate. Rinvoq® is a small molecule that inhibits Janus kinase (JAK), a protein that plays a role in inflammation.

Intended Audience

This report will be beneficial for every stakeholder of the immunosuppressive drugs market such as:

• Manufacturers of immunosuppressive drugs
• Medical research and development institutes
• Traders and distributors
• Medical professionals
• Patients

Report Overview

This report provides an in-depth analysis of the Immunosuppressive drugs market in terms of current value and future forecast. We have also identified the problems and prospects of the given market.Moreover, technological analysis of the product will greatly help to make decisions about investment in the product. Furthermore, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the Immunosuppressive drugs market.